J S Haug
Overview
Explore the profile of J S Haug including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vij R, Brown R, Shenoy S, Haug J, Kaesberg D, Adkins D, et al.
Bone Marrow Transplant
. 2000 Jun;
25(12):1223-8.
PMID: 10871725
GVHD is a significant cause of morbidity and mortality following allogeneic peripheral blood stem cell transplantation (AlloPBSC). CD34+ cell selection could reduce GVHD by negative selection of T cells. In...
2.
Faraday N, Rade J, Johns D, Khetawat G, Noga S, DiPersio J, et al.
Blood
. 1999 Dec;
94(12):4084-92.
PMID: 10590053
Investigation of the molecular basis of megakaryocyte (MK) and platelet biology has been limited by an inadequate source of genetically manipulable cells exhibiting physiologic MK and platelet functions. We hypothesized...
3.
Betsuyaku T, Liu F, Senior R, Haug J, Brown E, Jones S, et al.
J Clin Invest
. 1999 Mar;
103(6):825-32.
PMID: 10079103
Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor that is widely used to treat neutropenia. In addition to stimulating polymorphonuclear neutrophil (PMN) production, G-CSF may have significant effects on...
4.
Jacob J, Haug J, Raptis S, Link D
Blood
. 1998 Jul;
92(2):353-61.
PMID: 9657731
Granulocyte colony-stimulating factor (G-CSF) is the principal growth factor regulating the production of neutrophils, yet its role in lineage commitment and terminal differentiation of hematopoietic progenitor cells is controversial. In...
5.
BROWN R, Adkins D, Goodnough L, Haug J, Todd G, Wehde M, et al.
J Clin Oncol
. 1997 Sep;
15(9):3067-74.
PMID: 9294469
Purpose: To determine the number of CD34+ cells associated with a high probability of rapid engraftment after allogeneic peripheral-blood stem-cell (PBSC) transplant, and to examine the relationship between certain donor...
6.
Voziyan P, Haug J, MELNYKOVYCH G
Biochem Biophys Res Commun
. 1995 Jul;
212(2):479-86.
PMID: 7626062
Mechanism of the inhibitory effect of isoprenoid farnesol on cell proliferation has been studied in human acute leukemia CEM-C1 cells. Farnesol (20 microM) reduced the rate of radioactive label incorporation...
7.
Haug J, Goldner C, Yazlovitskaya E, Voziyan P, MELNYKOVYCH G
Biochim Biophys Acta
. 1994 Aug;
1223(1):133-40.
PMID: 8061045
Previously reported observations have shown that trans-trans farnesol inhibits incorporation of choline into phosphatidylcholine and reduces the growth rate of the human acute leukemia CEM-C1 cell line (Melnykovych, G., Haug,...
8.
Adany I, Yazlovitskaya E, Haug J, Voziyan P, MELNYKOVYCH G
Cancer Lett
. 1994 May;
79(2):175-9.
PMID: 8019976
Six neoplastically-derived cell lines and three cell lines derived from normal tissues were compared for their sensitivity to isoprenoid trans-trans farnesol. Assays of cell numbers and of protein concentrations per...
9.
MELNYKOVYCH G, Haug J, Goldner C
Biochem Biophys Res Commun
. 1992 Jul;
186(1):543-8.
PMID: 1632790
Acute leukemia cells of the established line CEM-C1 were treated during growth in serum-free medium with various concentrations of trans-trans farnesol. At concentrations ranging from 9.0 to 31.5 microM, farnesol...